Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`
`David L. Cavanaugh (Reg. No. 36,476)
`Rebecca A. Whitfield (Reg. No. 73,756)
`Robert J. Gunther, Jr. (Pro Hac Vice to be filed)
`WILMER CUTLER PICKERING
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`Adam R. Brausa (Reg. No.
`60,287)
`Daralyn J. Durie (Pro Hac Vice to be
`filed)
`Durie Tangri LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PFIZER, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`
`
`Case IPR2017-02019
`U.S. Patent 6,339,142
`
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION PRO HAC
`VICE OF DARALYN J. DURIE UNDER 37 C.F.R. § 42.10(C)
`
`
`
`
`
`
`

`

`
`I.
`
`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`RELIEF REQUESTED
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Genentech, Inc.
`
`(“Genentech”) by and through its attorneys, respectfully request that the Board
`
`admit Daralyn J. Durie pro hac vice in this proceeding, IPR2017-02019.
`
`Petitioner’s counsel has indicated that it does not oppose this motion.
`
`II. GOVERNING LAW, RULES, AND PRECEDENT
`Section 42.10(c) of 37 C.F.R. provides as follows:
`
`The Board may recognize counsel pro hac vice during a proceeding
`upon a showing of good cause, subject to the condition that lead counsel
`be a registered practitioner and to any other conditions as the Board may
`impose. For example, where the lead counsel is a registered practitioner,
`a motion to appear pro hac vice by counsel who is not a registered
`practitioner may be granted upon showing that counsel is an experienced
`litigating attorney and has an established familiarity with the subject
`matter at issue in the proceeding.
`
`The Board has specified that a motion for pro hac vice admission shall be
`
`filed in accordance with the “ORDER-AUTHORIZING MOTION FOR PRO HAC
`
`VICE ADMISSION – 37 C.F.R. § 42.10” in Unified Patents, Inc. v. Parallel Iron,
`
`LLC, Case No. IPR2013-00639 (“Representative Order”). The Representative
`
`Order states that the motion must “[c]ontain a statement of facts showing there is
`
`good cause for the Board to recognize counsel pro hac vice during the
`
`proceeding,” and “[b]e accompanied by an affidavit or declaration of the individual
`
`
`
`
`
`
`1
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`seeking to appear” which attests to a number of facts concerning the counsel
`
`seeking admission pro hac vice specified in the Representative Order.
`
`Accompanying this motion as Exhibit 2016 is the Declaration of Daralyn J. Durie
`
`in Support of this Motion for Admission Pro Hac Vice (“Durie Decl.”).
`
`III. STATEMENT OF FACTS
`1.
`Patent Owners’ lead counsel, David L. Cavanaugh, is a registered
`
`practitioner (Reg. No. 36,476). Backup counsel, Adam Brausa (Reg. No. 60,287)
`
`and Rebecca Whitfield (Reg. No. 73,756) are also registered practitioners.
`
`2. Ms. Durie is a Partner at the law firm Durie Tangri LLP. (Durie Decl.
`
`¶ 2, Ex. 2016).
`
`3. Ms. Durie is an experienced litigating attorney and has been litigating
`
`cases relating to patents for over 20 years. (Id. ¶ 2)
`
`4. Ms. Durie is a member in good standing of the California State Bar,
`
`and among other courts, the United States Court of Appeals for the Federal Circuit
`
`(Id. ¶ 3).
`
`5. Ms. Durie has never been suspended or disbarred from practice before
`
`any court or administrative body. (Id. ¶ 5).
`
`6.
`
`No application filed under Ms. Durie for admission to practice before
`
`any court or administrative body has ever been denied. (Id. ¶ 6).
`
`7.
`
`No sanctions or contempt citations have been imposed against Ms.
`
`
`
`
`
`
`2
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`Durie by any court or administrative body. (Id. ¶ 7).
`
`8. Ms. Durie has read and agrees to comply with the Office Patent Trial
`
`Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37
`
`C.F.R. (Id. ¶ 8).
`
`9. Ms. Durie understands that she will be subject to the USPTO Rules of
`
`Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`jurisdiction under 37 C.F.R. § 11.19(a). (Id. ¶ 9).
`
`10.
`
`In the last three (3) years, Ms. Durie have appeared Pro Hac Vice
`
`before the Patent Trial and Appeal Board in the following cases: Sanofi-Aventis
`
`U.S. LLC and Regeneron Pharmaceuticals, Inc. v. Genentech, Inc. and City of
`
`Hope, IPR2015-01624 (pro hac vice granted); Genzyme Corporation v. Genentech,
`
`Inc. and City of Hope, IPR2016-00460 (pro hac vice motion filed) (joined with
`
`IPR2015-01624); Genzyme Corporation v. Genentech, Inc. and City of Hope,
`
`IPR2016-00383 (pro hac vice motion filed) (not instituted); Merck Sharp &
`
`Dohme Corp. v. Genentech, Inc. and City of Hope, IPR2016-01373 (pro hac vice
`
`granted) (not instituted); Mylan Pharmaceuticals, Inc. v. Genentech, Inc. and City
`
`of Hope, IPR2016-00710 (pro hac vice granted) (joined with IPR2017-00047)
`
`(terminated); Mylan Pharmaceuticals, Inc. v. Genentech, IPR2016-01693 (pro hac
`
`vice motion filed) (challenging U.S. Patent No. 6,407,213, that patent at issue in
`
`this case; terminated); Mylan Pharmaceuticals, Inc. v. Genentech, IPR2016-01694
`
`
`
`
`
`
`3
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`(pro hac vice motion filed) (challenging U.S. Patent No. 6,407,213, that patent at
`
`issue in this case; terminated); Hospira, Inc.. v. Genentech, Inc., IPR2017-00731
`
`(institution denied July 27, 2017, request for rehearing filed August 25, 2017; pro
`
`hac vice granted October 2, 2017; instituted October 26, 2017, pending); Hospira,
`
`Inc. v. Genentech, Inc., IPR2017-00737 (pro hac vice granted June 21, 2017,
`
`pending); Hospira, Inc. v. Genentech, Inc., IPR2017-00739 (pro hac vice granted
`
`June 21, 2017; institution denied July 27, 2017); Hospira, Inc. v. Genentech, Inc.,
`
`IPR2017-00804 (pro hac vice granted October 2, 2017, pending); Hospira, Inc. v.
`
`Genentech, Inc., IPR2017-00805 (pro hac vice granted October 2, 2017, pending);
`
`Celltrion, Inc. v. Genentech, Inc., IPR2017-01121 (pro hac vice granted October
`
`30, 2017, pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01122 (pro hac
`
`vice granted October 30, 2017, pending); Celltrion, Inc. v. Genentech, Inc.,
`
`IPR2017-01139 (pro hac vice granted October 30, 2017, pending); Celltrion, Inc.
`
`v. Genentech, Inc., IPR2017-01140 (pro hac vice granted October 30, 2017,
`
`pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01373 (pro hac vice motion
`
`to be granted, pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01374 (pro
`
`hac vice motion to be granted, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-
`
`01488 (pro hac vice granted September 27, 2017, pending); Pfizer, Inc. v.
`
`Genentech, Inc., IPR2017-01489 (pro hac vice granted September 27, 2017,
`
`pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-01726 (pro hac vice motion to
`
`
`
`
`
`
`4
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`be filed, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-01727 (pro hac vice
`
`motion to be filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc.,
`
`IPR2017-01958 (pro hac vice motion to be filed, pending); Samsung Bioepis, Co.
`
`Ltd. v. Genentech, Inc., IPR2017-01959 (pro hac vice motion to be filed, pending);
`
`Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-01960 (joined to IPR2017-
`
`00737); Pfizer, Inc. v. Genentech, Inc., IPR2017-02020 (pro hac vice to be filed,
`
`pending); Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc.,
`
`IPR2017-02031 (pro hac vice to be filed, pending); Boehringer Ingelheim
`
`Pharmaceuticals, Inc. v. Genentech, Inc., IPR2017-02032 (pro hac vice to be filed,
`
`pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-02063 (pro hac vice to be filed,
`
`pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-02139 (pro hac
`
`vice to be filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-
`
`02140 (pro hac vice to be filed, pending); Pfizer, Inc. v. Genentech, Inc., IPR2018-
`
`00016 (pro hac vice to be filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech,
`
`Inc., IPR2018-00192 (pro hac vice to be filed, pending).
`
`11. Ms. Durie has an established familiarity with the subject matter at
`
`issue in this proceeding. She has handled patent cases relating to recombinant
`
`antibodies for more than twelve years. (Id. ¶ 11). In many of these cases involving
`
`antibodies, she has represented Genentech. During these litigations, she has
`
`worked closely with Adam R. Brausa, counsel for Genentech in this matter. (Id.).
`
`
`
`
`
`
`5
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`12. Additionally, Ms. Durie has carefully reviewed and has developed
`
`
`
`extensive familiarity with the matters involved in and implicated by these
`
`proceedings, including the ’213 patent and its file history, the prior art presented in
`
`the petition, and the legal and factual issues raised by the Petitioner in this
`
`proceeding. As a result, Ms. Durie has acquired substantial understanding of the
`
`underlying legal and technological issues at stake in this proceeding. (Id. ¶ 12).
`
`IV. GOOD CAUSE EXISTS FOR PRO HAC VICE ADMISSION OF
`DARALYN J. DURIE
`The facts outlined above in the Statement of Facts, supported by the
`
`Declaration of Daralyn J. Durie (Ex. 2016), establish there is good cause to admit
`
`Ms. Durie pro hac vice in this proceeding under 37 C.F.R. § 42.10. Patent
`
`Owner’s lead counsel, David L. Cavanaugh, is a registered practitioner in good
`
`standing before the Board. Ms. Durie is an attorney in good standing in the State
`
`Bar of California and the United States Court of Appeals for the Federal Circuit.
`
`Ms. Durie has carefully reviewed the ’142 patent at issue in this proceeding, its
`
`prosecution history, the prior art, the grounds advanced by the Petitioner and other
`
`aspects of the record in this proceeding, and is familiar with these matters. Based
`
`on her experience and knowledge, there is good cause to admit Ms. Durie pro hac
`
`vice in this proceeding.
`
`V. CONCLUSION
`In light of the foregoing, Patent Owner respectfully requests that the Board
`
`
`
`
`
`
`6
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`admit Daralyn J. Durie pro hac vice in this proceeding.
`
`
`
`Dated: January 2, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`David L. Cavanaugh, Reg. No. 36,476
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`1875 Pennsylvania Avenue, N.W.
`Washington, D.C. 20006
`Tel.: 202-663-6000
`Fax: 202-663-6363
`
`Attorney for Patent Owner
`Genentech, Inc.
`
`
`7
`
`
`
`

`

`
`
`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`PATENT OWNER’S EXHIBIT LIST
`IPR2017-02019
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit Name
`
`David Holzman, Gene Therapy for HER-2-Related Cancer,
`MOLECULAR MED. TODAY 138 (1996)
`Russ Hoyle, Genentech Is Poised for an Anti-Cancer
`Breakthrough, 16 NATURE BIOTECHNOLOGY 887 (1998)
`Jatinderpal Kalsi et al., Structure-Function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MED. 1-28
`(1999)
`Shohei Kishishita et al., Effect of Temperature Shift on Levels
`of Acidic Charge Variants in IgG Monoclonal Antibodies in
`Chinese Hamster Ovary Cell Culture, 119 J. BIOSCIENCE &
`BIOENGINEERING 700-705 (2015)
`Nigel Jenkins, Modifications of Therapeutic Proteins:
`Challenges and Prospects, 53 CYTOTECHNOLOGY 121-125
`(2007)
`Declaration of Carol Basey (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 2013)
`Declaration of Gregory Blank (submitted in European Patent
`Office, Case No. T 2522/10-3304) (Jan. 15, 2008)
`Declaration of John Simpson (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 24, 2013)
`Declaration of Laura Storto (submitted in European Patent
`Office, Case No. T 2522/10-3304) (July 15, 2013)
`Declaration of Dongyuan Wang (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 29, 2011)
`Declaration of Janet Yang (submitted in European Patent
`Office, Case No. T 2522/10-3304) (June 6, 2013)
`Matthias Brunner, Investigation of the Interactions of Critical
`Scale-Up Parameters (pH, pO2 and pCO2) on CHO Batch
`Performance and Critical Quality Attributes, 40 BIOPROCESS
`BIOSYST. ENG. 251-263 (2017)
`Michael J. Pikal et al., The Effects of Formulation Variables on
`the Stability of Freeze-Dried Human Growth Hormone, 8
`PHARM. RES. 427-436 (1991)
`
`
`
`
`
`
`8
`
`
`
`

`

`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`Patent Owner’s
`Exhibit Number
`2014
`
`
`2015
`
`2016
`
`
`
`
`
`Exhibit Name
`
`Srinivasa Rao et al., Separation of Monoclonal Antibodies by
`Weak Cation-Exchange Chromatography Using ProPac and
`ProSwift Columns (2010)
`Declaration of Robert J. Gunther, Jr. in support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in support of Motion for
`Admission Pro Hac Vice
`
`
`
`
`
`
`
`
`
`
`
`
`9
`
`
`
`

`

`
`
`Case No. IPR2017-02019
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`CERTIFICATE OF SERVICE
`I hereby certify that, on January 3, 2018, I caused a true and correct copy of
`the following materials:
`
` Patent Owner’s Unopposed Motion for Pro Hac Vice Admission of Daralyn
`J. Durie
`
` Exhibit 2016
`
`
`
` Patent Owner’s Updated Exhibit List
`
`to be served via electronic mail on the following attorneys of record:
`
`Amanda Hollis
`KIRKLAND & ELLIS LLP
`amanda.hollis@kirkland.com
`300 North LaSalle, Chicago, IL 60654
`
`Sarah K. Tsou
`KIRKLAND & ELLIS LLP
`sarah.tsou@kirkland.com
`601 Lexington Avenue, New York, NY 10022
`
`Karen Younkins
`KIRKLAND & ELLIS LLP
`karen.younkins@kirkland.com
`333 S. Hope Street, Los Angeles, CA 90071
`
`Katherine Rhoades
`KIRKLAND & ELLIS LLP
`katherine.rhoades@kirkland.com
`300 North LaSalle, Chicago, IL 60654
`
`Pfizer_Genentech_IPRs@kirkland.com
`
`
`/Rebecca A. Whitfield/
`Rebecca A. Whitfield
`Reg. No. 73,756
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`(617) 526-6505
`
`10
`
`
`
`
`
`
`
`
`
`
`